Denmark rejects Sobi's blood disease medicine due to "unreasonably high" price

Aspaveli is too expensive and cannot be recommended as a standard treatment for Danish patients, says the Danish Medicines Council.

Photo: John Ambrose / Sobi / PR

Danish patients will not be offered treatment with Aspaveli (pegcetacoplan), made by Swedish company Sobi, the Danish Medicines Council has decided according to media Hæmatologisk Tidsskrift, which covers news about blood diseases.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs